In addition, recent studies also showed that the inhibition of PRMT5 with immune checkpoint therapy diminished the growth of murine melanoma tumors and enhanced therapeutic efficacy [41], and suppressive macrophage infiltrates and exhausted-like phenotypes and tumor-associated antigen-specific CD8+ T cells were present during Akt/N-Ras-derived HCC progression [34,38,42]. This evidence concerns the gene PRMT5 and hepatocellular carcinoma.